Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 2/20 | 0.51 |
| ▸ | MLNR | O43193 | 4/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16456532 | 1.00 | OPRD1 (0.51) | OPRD1MLNROPRM1 | |
| SCHEMBL16456531 | 0.89 | OPRD1 (0.40) | OPRD1MLNROPRM1 | |
| SCHEMBL6466971 | 0.89 | OPRD1 (0.40) | OPRD1MLNROPRM1 | |
| SCHEMBL4576560 | 0.85 | OPRD1 (0.50) | OPRD1OPRM1 | |
| SCHEMBL12016528 | 0.80 | OPRD1 (0.45) | OPRD1OPRM1 | |
| SCHEMBL4576004 | 0.79 | OPRD1 (0.56) | OPRD1OPRM1 | |
| SCHEMBL12018158 | 0.79 | OPRD1 (0.56) | OPRD1OPRM1 | |
| SCHEMBL7623262 | 0.76 | MGLL (0.35) | OPRD1 | |
| SCHEMBL4576003 | 0.75 | OPRD1 (0.43) | OPRD1OPRM1 | |
| SCHEMBL8078564 | 0.72 | OPRD1 (0.81) | OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501513-B1 | COMPOSITIONS AND METHODS FOR COMBATING LOWER URINARY TRACT DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONISTS | VERSI GROUP LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8476280-B2 | Modulate contraction, relaxation of muscles | VERSI GROUP, LLC (US) | 2013-07-02 | — | — | US | disclosed |
| EP-1501513-A2 | COMPOSITIONS AND METHODS FOR COMBATING LOWER URINARY TRACT DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONISTS | Ardent Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040002503-A1 | Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists | VERSI GROUP, LLC | 2004-01-01 | — | — | US | disclosed |
| WO-2003094853-A2 | COMPOSITIONS AND METHODS FOR COMBATING LOWER URINARY TRACT DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONISTS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002503-A1 | Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885MLNR 229/4885OPRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.